Handelsbanken Fonder AB Sells 1,033 Shares of ICON Public Limited (NASDAQ:ICLR)

Handelsbanken Fonder AB decreased its holdings in shares of ICON Public Limited (NASDAQ:ICLR) by 4.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,676 shares of the medical research company’s stock after selling 1,033 shares during the period. Handelsbanken Fonder AB’s holdings in ICON Public were worth $4,336,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Steph & Co. boosted its position in shares of ICON Public by 3.7% during the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after purchasing an additional 55 shares in the last quarter. Arkadios Wealth Advisors raised its stake in ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after buying an additional 62 shares during the period. Sierra Ocean LLC acquired a new position in ICON Public during the 4th quarter worth approximately $29,000. First Horizon Advisors Inc. raised its stake in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the period. Finally, Park Place Capital Corp raised its stake in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after buying an additional 166 shares during the period. Institutional investors own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ICLR. Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price target (down from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Robert W. Baird dropped their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. JPMorgan Chase & Co. lowered their price objective on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Finally, Truist Financial lowered their price objective on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $281.00.

ICON Public Stock Performance

Shares of ICLR opened at $201.39 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $16.61 billion, a price-to-earnings ratio of 21.13, a PEG ratio of 1.86 and a beta of 1.19. The stock has a 50 day moving average of $202.90 and a 200 day moving average of $244.47. ICON Public Limited has a 12 month low of $181.51 and a 12 month high of $347.72.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.04 billion. As a group, sell-side analysts forecast that ICON Public Limited will post 13.38 earnings per share for the current year.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.